BioSpace News Archive

Emergent BioSolutions Inc. will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.

Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, announced that the Company will release its financial and business results for the half year ended June 30, 2021 on Thursday, August 12, 2021.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it will report its financial results for the second quarter of 2021 on Monday, August 9, 2021 before the opening of the U.S. financial markets.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021.

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, and Quality Assurance, is pleased to announce James Mullally, PhD, Former U.S. Food and Drug Administration Assistant Director of the Division of Chemistry and Toxicology Devices, has joined MCRA as Vice President, IVD Regulatory Affairs.

IMV Inc. announced the pricing of its previously-announced underwritten public offering of 14,285,714 units at a price to the public of US$1.75 per Unit, for aggregate gross proceeds to the Corporation of approximately US$25 million, before deducting underwriting commissions and Offering expenses and excluding any proceeds the Corporation may receive from the exercise of the underlying warrants.

Navidea Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company’s request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis (“RA”) and advancement to the pivotal Phase 3 trial.

Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies

TellBio, Inc. announces publication of data from the scientific founders showing high concordance of detecting ESR1 mutations in CTCs and ctDNA among patients diagnosed with ER-positive metastatic breast cancer.